Charles Baltic
Chairman at MEI PHARMA, INC.
Net worth: 17 221 $ as of 2024-04-29
Profile
Charles V.
Baltic is currently the Chairman at MEI Pharma, Inc., Chairman at AssayQuant Technologies, Inc., and Executive Vice President at SIDIS, Inc. He previously served as the Chief Executive Officer at Amyndas Pharmaceuticals LLC, Director-Life Science at Cowen & Co. (New York), Managing Director-Healthcare Investment Banking at Wachovia Securities LLC, Managing Director & Co-Head-Healthcare at Needham & Co. LLC, Managing Director at CRT Capital Group LLC, Director at MedVantage, Inc., Member at US Securities & Exchange Commission, Trustee at Washington Biotechnology & Biomedical Association, Founding Trustee at The Hope Funds for Cancer Research, and Chief Operations Officer at Sidis Corp.
Mr. Baltic has an undergraduate and graduate degree from Georgetown University and an MBA from The Wharton School of the University of Pennsylvania.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
MEI PHARMA, INC.
0.08% | 2023-10-29 | 5,555 ( 0.08% ) | 17 221 $ | 2024-04-29 |
Charles Baltic active positions
| Companies | Position | Start |
|---|---|---|
| MEI PHARMA, INC. | Chairman | 2023-01-04 |
| SIDIS, Inc. | Corporate Officer/Principal | 2018-12-31 |
| Assayquant Technologies, Inc. | Chairman | - |
Former positions of Charles Baltic
| Companies | Position | End |
|---|---|---|
Amyndas Pharmaceuticals LLC
 Amyndas Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Amyndas Pharmaceuticals LLC is an American clinical-stage biopharmaceutical company that focuses on developing advanced complement therapies to treat inflammatory disorders in areas of unmet medical need. The private company has a robust R & D complement program with a diversified pipeline of C3 complement inhibitors. The company's priority clinical programs focus on kidney transplantation, PNH, C3G, periodontitis, AMD, and cancer immunotherapy. The company's lead candidates are recognized by the scientific community as the best C3-based complement inhibitors currently in development. Charles V. Baltic has been the CEO of the company since 2021. | Chief Executive Officer | 2022-09-30 |
Sidis Corp
 Sidis Corp Financial ConglomeratesFinance Sidis Corp provides investment services for market-leading life science companies. | Chief Operating Officer | 2020-12-31 |
Needham & Co. LLC
 Needham & Co. LLC Investment Banks/BrokersFinance Needham & Co. LLC (Needham) is a registered investment advisor and broker/dealer headquartered in New York City. The firm was founded in 1985 and is a wholly-owned indirect subsidiary of The Needham Group, Inc. Needham provides corporate and institutional clients with high quality research, corporate access, capital markets and trading execution services in both the public and private markets, with an emphasis on growth companies. | Corporate Officer/Principal | 2018-12-31 |
| Washington Biotechnology & Biomedical Association | Director/Board Member | 2017-12-31 |
The Hope Funds for Cancer Research
 The Hope Funds for Cancer Research Miscellaneous Commercial ServicesCommercial Services The Hope Funds for Cancer Research provides funds for cancer research. The private company is based in Newport, RI. The company was founded by Leah Rush Cann. | Director/Board Member | 2016-12-31 |
Training of Charles Baltic
| Georgetown University | Graduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| MEI PHARMA, INC. | Health Technology |
| Private companies | 12 |
|---|---|
The Hope Funds for Cancer Research
The Hope Funds for Cancer Research Miscellaneous Commercial ServicesCommercial Services The Hope Funds for Cancer Research provides funds for cancer research. The private company is based in Newport, RI. The company was founded by Leah Rush Cann. | Commercial Services |
| Washington Biotechnology & Biomedical Association | |
CRT Capital Group LLC
 CRT Capital Group LLC Investment Banks/BrokersFinance Founded in 1989, CRT Capital Group LLC is an institutional securities research and brokerage firm located in Stamford, Connecticut. The firm focuses on high-yield and convertible debt, capital structure arbitrage, mergers and acquisitions, special situations and distressed securities. CRT trades senior and subordinated bonds, bank debt, trade claims, convertible bonds, equities, real estate loans, tax exempt securities and private placements. | Finance |
| MedVantage, Inc. | |
| SIDIS, Inc. | |
| US Securities & Exchange Commission | Finance |
Wachovia Securities LLC
 Wachovia Securities LLC Investment Banks/BrokersFinance Wachovia Securities LLC offered equity, fixed income, and structured products. It was founded in 2001 and was headquartered in St. Louis, MO. | Finance |
| Cowen & Co. (New York) | Finance |
Needham & Co. LLC
Needham & Co. LLC Investment Banks/BrokersFinance Needham & Co. LLC (Needham) is a registered investment advisor and broker/dealer headquartered in New York City. The firm was founded in 1985 and is a wholly-owned indirect subsidiary of The Needham Group, Inc. Needham provides corporate and institutional clients with high quality research, corporate access, capital markets and trading execution services in both the public and private markets, with an emphasis on growth companies. | Finance |
Sidis Corp
Sidis Corp Financial ConglomeratesFinance Sidis Corp provides investment services for market-leading life science companies. | Finance |
Amyndas Pharmaceuticals LLC
Amyndas Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Amyndas Pharmaceuticals LLC is an American clinical-stage biopharmaceutical company that focuses on developing advanced complement therapies to treat inflammatory disorders in areas of unmet medical need. The private company has a robust R & D complement program with a diversified pipeline of C3 complement inhibitors. The company's priority clinical programs focus on kidney transplantation, PNH, C3G, periodontitis, AMD, and cancer immunotherapy. The company's lead candidates are recognized by the scientific community as the best C3-based complement inhibitors currently in development. Charles V. Baltic has been the CEO of the company since 2021. | Health Technology |
| Assayquant Technologies, Inc. |
- Stock Market
- Insiders
- Charles Baltic